Translational Pharmacokinetic-Pharmacodynamic Modeling for an Orally Available Novel Inhibitor of Epigenetic Regulator Enhancer of Zeste Homolog 2
Shinji Yamazaki, Shikhar Sharma(Pfizer (United States)), Hovhannes J. Gukasyan(Pfizer (United States)), Sean Uryu(Pfizer (United States)), Hui Wang(Tibet Autonomous Region People's Hospital)
Cited by 8
Related Papers
Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)
|Journal of Medicinal Chemistry|2011|924
Epigenomic Profiling of Young and Aged HSCs Reveals Concerted Changes during Aging that Reinforce Self-Renewal
|Cell stem cell|2014|703
Dnmt3a regulates emotional behavior and spine plasticity in the nucleus accumbens
|Nature Neuroscience|2010|616
VEGF-Induced Vascular Permeability Is Mediated by FAK
|Developmental Cell|2012|339